See more : PCL, Inc. (241820.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Advaxis, Inc. (ADXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advaxis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TeamViewer AG (TMVWF) Income Statement Analysis – Financial Results
- Cielo S.A. (CIEL3.SA) Income Statement Analysis – Financial Results
- SGS SA (SGSN.SW) Income Statement Analysis – Financial Results
- Share India Securities Limited (SHAREINDIA.BO) Income Statement Analysis – Financial Results
- Lar España Real Estate SOCIMI, S.A. (LRE.MC) Income Statement Analysis – Financial Results
Advaxis, Inc. (ADXS)
About Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.00K | 250.00K | 3.24M | 253.00K | 2.33M | 6.06M | 12.03M | 3.99M | 0.00 | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Cost of Revenue | 13.00K | 314.00K | 3.71M | 1.29M | 1.29M | 0.00 | 0.00 | 0.00 | 265.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -64.00K | -468.00K | -1.03M | 1.05M | 6.06M | 12.03M | 3.99M | -265.39K | 1.00M | 0.00 | 0.00 | 0.00 | 508.48K | 29.69K | 65.74K | 154.20K | 431.96K | 552.87K | 116.41K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -25.60% | -14.44% | -407.91% | 44.94% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 24.08M | 7.61M | 10.56M | 15.61M | 14.42M | 56.97M | 71.90M | 48.77M | 24.22M | 8.69M | 5.62M | 6.65M | 8.08M | 4.90M | 2.32M | 2.48M | 2.13M | 1.40M | 1.18M | 125.94K | 0.00 | 0.00 |
| General & Administrative | 12.19M | 9.74M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Selling & Marketing | 0.00 | -473.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.19M | 8.42M | 11.46M | 11.09M | 4.34M | 19.47M | 38.66M | 31.71M | 24.45M | 11.85M | 9.07M | 5.69M | 4.94M | 3.53M | 2.70M | 3.04M | 2.63M | 2.08M | 1.22M | 524.37K | 10.00K | 10.00K |
| Other Expenses | 0.00 | 3.05M | -1.00K | -3.00K | 0.00 | -63.00K | -123.00 | -201.00 | -35.08K | 6.24K | -3.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.27M | 16.03M | 22.03M | 26.70M | 18.76M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Cost & Expenses | 36.28M | 16.34M | 22.03M | 26.70M | 20.05M | 76.44M | 110.56M | 80.49M | 48.67M | 20.54M | 14.69M | 12.33M | 13.02M | 8.43M | 5.02M | 5.52M | 4.76M | 3.48M | 2.40M | 650.31K | 10.00K | 10.00K |
| Interest Income | 28.00K | 74.00K | 5.00K | 110.00K | 225.00K | 577.00K | 669.76K | 331.53K | 114.22K | 36.31K | 5.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 15.75M | 0.00 | 260.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.25K | 987.75K | 4.54M | 4.70M | 3.81M | 851.01K | 0.00 | 0.00 | 0.00 | 36.67K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 369.00K | 314.00K | 990.00K | 1.98M | 1.48M | 1.50M | 1.12M | 536.19K | 265.39K | 203.30K | 178.64K | 161.78K | 160.69K | 138.95K | 111.16K | 197.35K | 263.78K | 144.39K | 41.10K | 15.82K | 0.00 | 0.00 |
| EBITDA | -35.87M | -15.78M | -18.77M | -24.39M | -17.56M | -72.28M | -97.43M | -76.03M | -48.36M | -19.29M | -18.04M | -12.17M | -13.78M | -7.79M | -4.88M | -5.30M | -7.09M | -193.70K | -1.80M | -518.14K | -10.00K | -10.00K |
| EBITDA Ratio | -275,915.38% | -6,310.40% | -579.20% | -9,641.90% | -752.40% | -1,192.12% | -809.80% | -1,903.07% | 0.00% | -1,929.27% | 0.00% | 0.00% | 0.00% | -1,531.44% | -16,422.51% | -8,064.18% | -4,601.10% | -44.84% | -325.82% | -445.12% | 0.00% | 0.00% |
| Operating Income | -36.27M | -16.09M | -18.79M | -26.45M | -17.71M | -70.38M | -98.53M | -76.49M | -48.67M | -19.54M | -14.69M | -12.33M | -13.02M | -7.93M | -4.99M | -5.45M | -4.60M | -3.05M | -1.84M | -533.90K | -10.00K | -10.00K |
| Operating Income Ratio | -278,969.23% | -6,436.00% | -579.81% | -10,454.15% | -758.83% | -1,160.79% | -818.95% | -1,914.77% | 0.00% | -1,953.86% | 0.00% | 0.00% | 0.00% | -1,558.76% | -16,796.90% | -8,293.45% | -2,985.06% | -705.91% | -333.25% | -458.66% | 0.00% | 0.00% |
| Total Other Income/Expenses | -16.72M | 1.78M | 974.00K | 30.00K | 225.00K | 3.91M | 20.03K | 68.85K | -84.03K | 625.33K | -5.03M | 4.45M | 10.15M | 649.70K | 5.85M | 46.63K | 2.76M | -2.71M | 36.67K | 57.00 | 0.00 | 0.00 |
| Income Before Tax | -51.98M | -14.31M | -17.81M | -26.42M | -17.49M | -66.47M | -97.84M | -76.09M | -48.64M | -18.88M | -20.71M | -12.42M | -8.50M | -11.09M | 7.22K | -5.41M | -1.85M | -5.76M | -1.81M | -533.85K | -10.00K | -10.00K |
| Income Before Tax Ratio | -399,876.92% | -5,723.60% | -549.75% | -10,442.29% | -749.19% | -1,096.24% | -813.21% | -1,904.75% | 0.00% | -1,888.22% | 0.00% | 0.00% | 0.00% | -2,181.24% | 24.32% | -8,222.52% | -1,197.96% | -1,333.56% | -326.62% | -458.61% | 0.00% | 0.00% |
| Income Tax Expense | -3.91M | 50.00K | 50.00K | 50.00K | 306.00K | 50.00K | -4.40M | -2.54M | -1.61M | -2.36M | -725.19K | -346.79K | -379.47K | -278.98K | -922.02K | -35.37K | -2.15M | 3.15M | -36.67K | 4.17K | 0.00 | 0.00 |
| Net Income | -48.07M | -14.36M | -17.86M | -26.47M | -17.79M | -66.52M | -93.44M | -73.56M | -47.03M | -16.53M | -19.99M | -12.07M | -8.12M | -10.81M | 929.24K | -5.42M | -2.45M | -6.20M | -1.81M | -538.08K | -10.00K | -10.00K |
| Net Income Ratio | -369,784.62% | -5,743.60% | -551.30% | -10,462.06% | -762.30% | -1,097.06% | -776.62% | -1,841.27% | 0.00% | -1,652.53% | 0.00% | 0.00% | 0.00% | -2,126.37% | 3,129.82% | -8,239.65% | -1,591.72% | -1,434.79% | -326.62% | -462.24% | 0.00% | 0.00% |
| EPS | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| EPS Diluted | -7.99 | -7.90 | -11.07 | -34.71 | -93.60 | -19.37 | -34.58 | -31.17 | -25.17 | -14.49 | -59.83 | -70.60 | -68.27 | -134.35 | 1.21K | -90.76 | -98.58 | -300.70 | -94.62 | -9.02 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
| Weighted Avg Shares Out (Dil) | 6.02M | 1.82M | 1.61M | 762.55K | 190.10K | 3.43M | 2.70M | 2.36M | 1.87M | 1.14M | 334.08K | 170.96K | 118.88K | 80.48K | 61.60K | 59.68K | 24.90K | 20.61K | 19.08K | 59.68K | 145.64M | 145.64M |
J&K: Most habeas corpus cases dragged on as court slammed govt on due process
However, in the 17 cases, where the court did quash the detention orders, it made significant observations, putting under the scanner, the procedure followed by the government while invoking the draconian PSA.
Public Storage Announces Appointment of Chief Administrative Officer
Public Storage (NYSE:PSA) (the “Company”) announced today the appointment of Natalia N. Johnson, the Company’s current Chief Human Resources Officer,
Most habeas corpus cases dragged on as court slammed govt on due process
However, in the 17 cases, where the court did quash the detention orders, it made significant observations, putting under the scanner, the procedure followed by the government while invoking the draconian PSA.
For Mehbooba Mufti’s release, a poke at Centre from Rahul and Priyanka Gandhi
On Friday, the Jammu and Kashmir administration extended Mufti’s detention even as it released Peoples Conference chief Sajad Gani Lone in Srinagar, a week ahead of the one-year anniversary of the revocation of the troubled region’s special status and its...
High time Mehbooba Mufti is released from detention: Rahul Gandhi to Centre
The former party president also accused the central government of undermining democracy by extending the detention of the former Jammu and Kashmir Chief Minister.
Rahul Gandhi accuses Centre of 'illegally' detaining Mehbooba Mufti, Union minister reminds him history
As Rahul Gandhi targeted the Central government for "illegally" detaining Mehbooba Mufti and other political leaders, Union Minister Jitendra Singh took a dig at the Congress leader by reminding him about the "infamous" history of the detention of Sheikh Abdullah...
'High time Mehbooba Mufti is released': Rahul Gandhi to Centre
'India's democracy is damaged when GOI illegally detains political leaders,' the Congress leader tweeted
India's democracy damaged, high time to release Mehbooba: Rahul Gandhi
P Chidambaram said that the extension of the detention of former Jammu and Kashmir CM Mehbooba Mufti under the PSA is an abuse of law
El león va por libre en la selva automovilística
La estrategia del grupo francés PSA de evitar producir hasta la recuperación del mercado le salva de los números rojos en el primer semestre
Extending Mehbooba Mufti's detention is abuse of law: P Chidambaram
P Chidambaram said extending Mehbooba Mufti's detention under PSA is an abuse of law and an assault on the constitutional rights guaranteed to every citizen,
Source: https://incomestatements.info
Category: Stock Reports